Connect Biopharma Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Connect Biopharma Holdings Limited income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Jan 2022Dec 2020
Revenue & Gross Profit
Revenue26.030.000.000.000.00
Cost of Revenue0.000.00-7.990.000.00
Gross Profit26.030.007.990.000.00
Operating Expenses
Research & Development29.260.5393.6580.5023.12
Selling, General & Administrative19.238.8620.0219.017.31
Operating Expenses48.4966.43101.2497.6629.36
Operating Income-22.45-66.43-101.24-97.66-29.36
Other Income/Expense
Interest Income4.455.221.810.170.21
Interest Expense0.000.02-0.02-0.01-0.44
Other Income/Expense7.05-4.09-0.92-103.98-88.73
Income
Income Before Tax-15.41-59.38-795.02-202.00-119.36
Income Tax Expense0.220.122.000.270.00
Net Income-15.63-59.50-124.55-202.27-119.36
Net Income - Continuous Operations-15.63-62.11-118.09-202.270.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-21.79-58.37-802.10-97.17-29.21
EBIT-22.45-59.36-795.16-97.66-29.36
Depreciation & Amortization0.660.99-6.940.490.15
Earnings Per Share
Basic EPS--1.00-14.00-4.00-7.00
Diluted EPS--1.00-2.00-4.00-7.00
Basic Shares Outstanding55.2155.0755.0452.1817.09
Diluted Shares Outstanding55.2155.0759.3152.1817.09